Fenmetozole

Fenmetozole

SCHEMBL635495

Clc1ccc(OCC2=NCCN2)cc1Cl

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 12/20 0.65
MAOA P21397 3/20 0.60
MAOB P27338 3/20 0.60
HTR1A P08908 4/20 0.48
ADRA2A P08913 4/20 0.48
ADRA2B P18089 4/20 0.48
ADRA2C P18825 4/20 0.48
ADRA1A P35348 5/20 0.47
ADRA1D P25100 3/20 0.46
ADRA1B P35368 3/20 0.46
TAAR1 Q96RJ0 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
THRB P10828 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
THPO P40225 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenmetozole SCHEMBL30295426 1.00 NISCH (0.65) NISCHMAOAMAOBHTR1AADRA2A
Fenmetozole SCHEMBL29913217 0.98 NISCH (0.63) NISCHMAOAMAOBHTR1AADRA2A
Fenmetozole SCHEMBL635494 0.98 NISCH (0.63) NISCHMAOAMAOBHTR1AADRA2A
SCHEMBL3178323 0.87 NISCH (0.60) NISCHMAOAMAOBHTR1AADRA2A
SCHEMBL11265808 0.87 NISCH (0.60) NISCHMAOAMAOBHTR1AADRA2A
SCHEMBL8155449 0.87 NISCH (0.60) NISCHMAOAMAOBHTR1AADRA2A
SCHEMBL3173356 0.87 NISCH (0.60) NISCHMAOAMAOBHTR1AADRA2A
Fenmetozole SCHEMBL11252776 0.83 ADRA1A (0.48) NISCHMAOAMAOBHTR1AADRA2A
SCHEMBL3172922 0.83 NISCH (0.71) NISCHMAOAMAOBHTR1AADRA2A
Hydrochloric Acid SCHEMBL11251146 0.81 NISCH (0.69) NISCHMAOAMAOBHTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220034911-A1 METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES VEGA JOSE (US) 2022-02-03 US claimed
WO-2020055762-A1 METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES VEGA JOSE (US) 2020-03-19 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 CN claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-2173720-A2 2-IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) F. Hoffmann-Roche AG (CH) 2010-04-14 EP claimed
US-7652055-B2 2-imidazolines HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US claimed
US-20090018180-A1 2-IMIDAZOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-15 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
WO-1997047293-A1 USE OF PREPARATIONS CONTAINING OPIATE ANTAGONISTS AND AGONISTS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF MIGRAINES VIVA DIAGNOSTIKA DIAGNOSTISCHE PRODUKTE GMBH (DE) 1997-12-18 WO claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 WO claimed
US-4344958-A BLOOD DISORDERS THE DOW CHEMICAL COMPANY (US) 1982-08-17 US claimed
US-4141985-A Alleviation of minimal brain dysfunction with 2-[(3,4-dichlorophenoxy)methyl]-2-imidazoline THE DOW CHEMICAL COMPANY (US) 1979-02-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018180-A1 2-IMIDAZOLINES TAAR1, TAAR5, NPY1R NISCH 2014/4885MAOA 67/4885MAOB 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.